GET DAILY SIGNALSNeuroPace (NPCE) Shares Drop -54% on Revenue Shortfall and Guidance Reduction
Key Takeaways
- NeuroPace (NPCE) shares have declined roughly 54% over the past 30 days, driven primarily by a third-quarter revenue miss and reduced full-year guidance announced on November 12, 2026.
- Third-quarter revenue of $23.1 million fell about 15% short of consensus estimates near $27 million, while management lowered its 2026 revenue outlook to a range of $91 million to $92 million from $99.5 million to $101.5 million.
- Management attributed the shortfall to isolated issues at several large accounts and disruption from a reorganized sales force, framing the setback as an execution problem rather than a decline in underlying patient demand.
- Sell-side sentiment turned sharply negative, with Leerink downgrading the stock to Market Perform and cutting its price target from $20 to $7, and Wells Fargo moving to Equal Weight from Overweight.
- Over the last quarter, the shares have fallen approximately 60%, extending a multi-month downtrend from their summer highs before the post-earnings selloff accelerated the decline.
NeuroPace's Business and Market Position
NeuroPace, Inc. is a commercial-stage medical device company based in Mountain View, California, focused on treating drug-resistant focal epilepsy. Its flagship product, the RNS System, is a brain-responsive neuromodulation platform that continuously monitors electrical activity in the brain and delivers targeted stimulation at the seizure source in real time. The system includes an implantable neurostimulator, depth and cortical strip leads, a patient remote monitor, and clinician-facing software such as the nSight Platform and Patient Data Management System.
The company sells primarily to comprehensive epilepsy centers, neurosurgeons, and neurologists in the United States, generating revenue through device sales and related accessories, with procedures reimbursed by insurers and government payers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow NPCE for its differentiated, data-rich technology and its pipeline of potential indication expansions, including idiopathic generalized epilepsy (IGE) and adolescent focal epilepsy, which management views as significant long-term growth opportunities.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NPCE shares have fallen from a closing price of about $12.56 in mid-October to roughly $5.79, a decline of approximately 54%. The move was heavily back-loaded, with the vast majority of the loss occurring after the company reported third-quarter results and reduced its outlook on November 12, 2026.
The quarterly trend is even steeper. From a mid-August close near $14.77, the stock has dropped about 60%, reflecting a steady slide through September and October before the earnings-driven collapse. The stock entered the report already under pressure, then broke decisively below its prior 52-week low as investors reassessed the company's growth trajectory.
What Drove the Recent Price Action
The dominant catalyst was NeuroPace's third-quarter earnings release. Total revenue came in at $23.1 million, below analyst estimates of roughly $27.1 million, with RNS System revenue growing only about 1% year over year. Management also cut full-year 2026 revenue guidance to $91 million to $92 million, down from a prior range of $99.5 million to $101.5 million, and described the quarter as falling short of expectations.
On the earnings call, Chief Executive Officer Joel Becker attributed the shortfall to account-specific issues at several high-volume centers, including staffing changes and scheduling constraints, as well as disruption from a reorganized sales force. The company reported a GAAP net loss of $3.3 million, narrowing from $4.9 million a year earlier, with non-GAAP gross margin improving to 84.8% and adjusted EBITDA turning positive at $0.4 million. Despite these operating improvements, the top-line miss and guidance cut overshadowed the results.
Analyst reactions compounded the selling pressure. Leerink downgraded NPCE to Market Perform from Outperform, lowering its price target from $20 to $7, while Wells Fargo moved to Equal Weight from Overweight. KeyBanc maintained an Overweight rating but trimmed its target from $18 to $14. The combination of a revenue shortfall, reduced guidance, and multiple downgrades drove the stock sharply lower in after-hours and subsequent trading.
Broader Context Behind the Quarterly Decline
Over the past quarter, NPCE's decline reflects a broader loss of momentum that began well before the earnings report. After trading near $16 in late June and into early July, the shares steadily drifted lower through August and September, pressured by weaker small-cap growth sentiment and lingering questions about the pace of RNS System adoption. The company's cash position also tightened, with cash and equivalents reported at $10.5 million as of September 30, 2026, down from $21.7 million a year earlier.
The strategic exit from its former SEEG distribution business (DIXI Medical) and the ongoing investment in clinical programs and a next-generation device platform kept expenses elevated relative to revenue growth. The third-quarter results ultimately crystallized these concerns, converting a gradual decline into a sharp repricing as investors discounted the near-term growth outlook.
Key Factors to Monitor Going Forward
Looking ahead, investors will be monitoring whether fourth-quarter procedure volumes recover as management indicated. The company said scheduled cases had begun to improve, and its preliminary 2027 outlook calls for core RNS revenue growth of approximately 15%, accelerating toward 20% as the year progresses. The timing and outcome of the FDA review for the IGE indication expansion remain key catalysts, with management planning for a potential approval by mid-2027 following a year-end 2026 submission amendment.
Other factors to watch include progress on the Remote Care submission, the AURORA study supporting adolescent focal epilepsy, reimbursement updates, and the company's cash runway. Macroeconomic conditions, including interest-rate expectations, could also influence sentiment toward this small-cap growth name. These are factual drivers to monitor rather than forecasts of future performance.
AI Tools in My Research Process
From what I see, automated strategies can offer useful context on names moving sharply on news. I often review Tickeron's Trending AI Robots to observe how different algorithmic approaches are positioned around volatility like the recent move in NPCE. It helps highlight data-driven responses across varying market conditions without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
NPCE sees MACD Histogram just turned negative
NPCE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 45 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NPCE as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NPCE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for NPCE entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NPCE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where NPCE advanced for three days, in 236 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
NPCE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NPCE's P/B Ratio (36.106) is slightly higher than the industry average of (4.142). P/E Ratio (-21.930) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.427) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. NPCE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NPCE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement